Clinical Trials Logo

Fetal Growth Restriction (FGR) clinical trials

View clinical trials related to Fetal Growth Restriction (FGR).

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT02442492 Terminated - Clinical trials for Intrauterine Growth Restriction (IUGR)

Sildenafil Therapy In Dismal Prognosis Early-Onset Intrauterine Growth Restriction

STRIDERCan
Start date: January 2017
Phase: Phase 2/Phase 3
Study type: Interventional

Early-onset placental intrauterine growth restriction (EO IUGR) is associated with a high risk of perinatal morbidity and mortality. In association with reduced circulating placental growth factor (PlGF) EO IUGR results from abnormal placentation with inadequate remodelling of the maternal uteroplacental arteries. There is no known treatment for placental IUGR. Management involves intensive fetal surveillance with delivery with evidence of serious fetal compromise. However, remote from term, delivery is associated with significant perinatal mortality and morbidity. Sildenafil vasodilates the uteroplacental vessels of IUGR-affected pregnancies and may represent a novel therapy.